Powered by

-BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site

Nov 26, 2019 - ENP Newswire

NEW YORK - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that The Mount Sinai Medical Center, internationally acclaimed for its excellence in research, patient care, and education in multiple sclerosis and across a range of medical specialties, has contracted with BrainStorm as a clinical study site for the Company's Phase 2 open-label, multicenter study of repe...